Fitc hla a b c antibody

Manufactured by BioLegend

The FITC HLA-A/B/C antibody is a fluorescently-labeled monoclonal antibody that binds to the major histocompatibility complex (MHC) class I proteins HLA-A, HLA-B, and HLA-C, which are expressed on the surface of most nucleated cells. This antibody is conjugated with the fluorescent dye FITC (fluorescein isothiocyanate) and can be used to detect and quantify the expression of these MHC class I proteins in various applications, such as flow cytometry and immunohistochemistry.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using fitc hla a b c antibody

Multi-Parametric Flow Cytometry and Molecular Analyses

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

For multi-parametric flow cytometry, immunofluorescence/immunohistochemistry and DEPArray analyses, primary antibodies were obtained from the following sources: FITC-CD45 (#304054; 1:200), FITC-CD34 (#343504; 1:200), FITC-CD105 (#323204; 1:200), FITC-CD90 (#328108; 1:200), FITC-CD73 (#344016; 1:200), FITC HLA-A/B/C antibody (#311404; 1:200), PerCP/Cy5.5-CD146 (#342014; 1:100), PE-Human NG2/MCSP (#FAB2585P, 1:100), BV421-Ki67 (#350506; 1:100), were obtained from Biolegend, Inc. APC-Cy7-CD44 (#103028, 1:100) BV510-CD24 (#311126, 1:100), PE-Pan-Cytokeratin (#5075, 1:100) were purchased from Cell Signaling Technology, Inc. Anti-Mel-A antibody (# AC12-0297-03; 1:200) was obtained from Abcore, and FITC-Anti-S100 (#ab76749; 1:50) was purchased from Abcam. For immunohistochemistry, anti-human, anti-Mel-A antibody (# ab51061; 1:100), HLA-ABC (#565292; 1:100) were obtained from BD Biosciences, Inc. (San Jose, CA, USA). Anti-mouse secondary IgG anti-human antibodies used for IHC staining were received from Santa Cruz Biotechnology, Inc. Antibodies for immunofluorescence staining were obtained from Cell Signaling Technology, Inc. (1:500 dilution of stock solution), as previously described [3 (link),22 (link)]. NRF2 inhibitor ML385 (#2114) was obtained from Cayman, Inc. while Nodal inhibitor Lefty (746-LF/CF) was purchased from R&D Systems, Inc. (Waltham, MA, USA).

Sprouse M.L., Welte T., Boral D., Liu H.N., Yin W., Vishnoi M., Goswami-Sewell D., Li L., Pei G., Jia P., Glitza-Oliva I.C, & Marchetti D. (2019). PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling. International Journal of Molecular Sciences, 20(8), 1916.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry and Immunohistochemistry

Check if the same lab product or an alternative is used in the 5 most similar protocols

For multi-parametric flow cytometry and DEPArray, primary antibodies were obtained from the following sources: FITC-CD45 (#304054; 1:200), FITC-CD34 (#343504; 1:200), FITC-CD105 (#323204; 1:200), FITC-CD90 (#328108; 1:200), FITC-CD73 (#344016; 1:200), FITC HLA-A/B/C antibody (#311404; 1:200), PerCP/Cy5.5-CD146 (#342014; 1:100), PE-Human NG2/MCSP (#FAB2585P, 1:100), BV421-Ki67 (#350506; 1:100), were obtained from Biolegend, anti-Melan-A antibody (# AC12-0297-03; 1:200) from Abcore, and FITC-Anti-S100 (#ab76749; 1:50) was purchased from Abcam.
For immunohistochemistry, anti-human, anti-Melan-A antibody (# ab51061; 1:100), anti-tenascin-C (# ab108930, 1:100) and anti-p21 (#ab188224, 1:100) were purchased from Abcam, HLA-ABC (#565292; 1:100) from BD Biosciences, USP7 (#GTX125894; 1:200) from Genetex, and PTEN antibody (# sc-7974; 1:20) was purchased from Santa Cruz Biotechnology, anti-p53 antibody (#SAB4503021, 1:100) was purchased from Sigma, CCP110 (#12780-I-AP, 1:100) antibody was obtained from Proteintech. Anti-mouse, USP7 (#26948-1-AP, 1:200) and PTEN (#603000-1-Ig, 1:200) antibodies were purchased from Proteintech, Alexafluor-conjugated anti-mouse, anti-rabbit secondary IgG antibodies used for immunofluorescence staining (1:500 dilution) were obtained from Cell Signaling Technology. USP7 inhibitors P5091 (#SML0770) and P22077 (#2301) were purchased from Biovision.

Vishnoi M., Boral D., Liu H., Sprouse M.L., Yin W., Goswami-Sewell D., Tetzlaff M.T., Davies M.A., Glitza Oliva I.C, & Marchetti D. (2018). Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. Cancer research, 78(18), 5349-5362.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!